Arch Biopartners Inc.
ARCH.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -116.28% | 6.04% | 7.93% | -44.06% | -36.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -116.28% | 6.04% | 7.93% | -44.06% | -36.29% |
| Cost of Revenue | -22.75% | 105.87% | 80.06% | -56.63% | -57.97% |
| Gross Profit | -1,349.87% | -4,953.73% | -1,227.81% | 84.99% | 110.97% |
| SG&A Expenses | -33.13% | -15.96% | -35.19% | -34.74% | -31.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.49% | 50.99% | 14.54% | -47.26% | -46.55% |
| Operating Income | -52.63% | -108.34% | -19.07% | 49.35% | 53.48% |
| Income Before Tax | -38.40% | -80.81% | -17.46% | 37.33% | 45.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.40% | -80.81% | -17.46% | 37.33% | 45.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.40% | -80.81% | -17.46% | 37.33% | 45.04% |
| EBIT | -52.63% | -108.34% | -19.07% | 49.35% | 53.48% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -37.55% | -80.17% | -17.47% | 37.73% | 45.24% |
| Normalized Basic EPS | -37.11% | -78.77% | -17.41% | 37.62% | 44.79% |
| EPS Diluted | -37.55% | -80.17% | -17.47% | 37.73% | 45.24% |
| Normalized Diluted EPS | -37.11% | -78.77% | -17.41% | 37.62% | 44.79% |
| Average Basic Shares Outstanding | 1.46% | 0.65% | -0.29% | 0.52% | 0.49% |
| Average Diluted Shares Outstanding | 1.46% | 0.65% | -0.29% | 0.52% | 0.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |